drugset / Trial / NCT04777422
Defibrotide in Children With High Risk Kawasaki Disease
Phase 2
Unknown
2 enrolled
New York Medical College
Columbia University · collabJohns Hopkins University · collabNew York University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the safety of defibrotide with IVIG in children with high risk Kawasaki disease.
Timeline
- Start
- 2021-02-24
- Primary completion
- 2023-10-24
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Defibrotide | Oligonucleotide (other) | 6.25 mg/kg | Intravenous |